Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy

NCT00310843 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00310843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
February 28, 2006
Completion date
Not reported
Enrollment
889 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections